BioStock: Stayble Therapeutics strengthened in 2021

In 2021, Stayble Therapeutics made progress in the development of a disease-modifying injection treatment for chronic discogenic low back pain. During the year, Stayble Therapeutics was strengthened with the recruitment of several key persons and an oversubscribed share issue. Finally, they were able to present positive interim results from the phase IIb study with STA363. BioStock contacted CEO Andreas Gerward to get his thoughts on the past year and what to expect next.

Read the interview with Stayble Therapeutics' CEO Andreas Gerward at biostock.se:

https://www.biostock.se/en/2021/12/stayble-therapeutics-strengthened-in-2021/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se